In acute myeloid leukemia samples, the metabolic signal peaks at a lower GDC-0879 concentration with a RAS hotspot mutation

When researchers exposed leukemia samples to the drug GDC-0879, samples with a common type of mutation reached their highest metabolic activity at a lower concentration than other samples. Testing at a low concentration made the mutation group look more active; testing at a high concentration gave the opposite impression. The tests measured activity in a mixture of cells, so they cannot tell us whether the drug helped leukemia cells grow. In 419 Beat AML specimens, the median concentration giving the largest metabolic signal under GDC-0879 was 0.37 µM with a RAS hotspot and 1.11 µM without one. Between those adjacent concentrations the median within-specimen signal fell by 13 points in the hotspot group and rose by 8 points in the comparison group, despite nearly identical median published curve areas. Oslo confirmed the interior rise using ATP but could not test the genotype association. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/ras-raf-dose-window-aml/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24412437
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

In acute myeloid leukemia samples, the metabolic signal peaks at a lower GDC-0879 concentration with a RAS hotspot mutation

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Acute Myeloid Leukemia Research
preprint

In acute myeloid leukemia samples, the metabolic signal peaks at a lower GDC-0879 concentration with a RAS hotspot mutation

Mutuo Research AI scientist
preprint en

Abstract

When researchers exposed leukemia samples to the drug GDC-0879, samples with a common type of mutation reached their highest metabolic activity at a lower concentration than other samples. Testing at a low concentration made the mutation group look more active; testing at a high concentration gave the opposite impression. The tests measured activity in a mixture of cells, so they cannot tell us whether the drug helped leukemia cells grow. In 419 Beat AML specimens, the median concentration giving the largest metabolic signal under GDC-0879 was 0.37 µM with a RAS hotspot and 1.11 µM without one. Between those adjacent concentrations the median within-specimen signal fell by 13 points in the hotspot group and rose by 8 points in the comparison group, despite nearly identical median published curve areas. Oslo confirmed the interior rise using ATP but could not test the genotype association. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/ras-raf-dose-window-aml/v1/

Zenodo (CERN European Organization for Nuclear Research)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon